Arguments in favour of remdesivir for treating SARS-CoV-2 infections

Wen-Chien Ko , Jean-Marc Rolain (1, 2) , Nan-Yao Lee , Po-Lin Chen , Ching-Tai Huang , Ping-Ing Lee , Po-Ren Hsueh

1 MEPHI - Microbes évolution phylogénie et infections
2 IHU Marseille - Institut Hospitalier Universitaire Méditerranée Infection

Domains: Life Sciences [q-bio]; Microbiology and Parasitology; Bacteriology; Life Sciences [q-bio]; Microbiology and Parasitology; Virology; Life Sciences [q-bio]; Microbiology and Parasitology; Parasitology; Life Sciences [q-bio]; Human health and pathology; Cardiology and cardiovascular system; Life Sciences [q-bio]; Human health and pathology; Emerging diseases; Life Sciences [q-bio]; Human health and pathology; Infectious diseases

Wen-Chien Ko, Jean-Marc Rolain, Nan-Yao Lee, Po-Lin Chen, Ching-Tai Huang, et al.. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. International Journal of Antimicrobial Agents, 2020, pp.105933. ⟨10.1016/j.ijantimicag.2020.105933⟩. ⟨hal-02509378⟩